RS-2026-25502043

Development of AI platform-based AAV engineering and gene therapy for choroideremia

Aavatar Therapeutics

AAVATAR THERAPEUTICS

OPHTHALMOLOGY | **Hit**

Product Type	Gene & Nucleic acids
Indication	Choroideremia
Target	CHM gene
MoA(Mechanism of Action)	AAV-mediated gene augmentation therapy
Competitiveness	• The previous AAV2-REP1 gene therapy (timrepigene emparvovec, Biogen) failed clinically due to the intrinsic limitations of the wild-type AAV2 capsid. • There are currently no active or newly initiated clinical trials of AAV-based therapies for choroideremia
Development Stage	Hit
Route of Administration	Intravitreal injection